| Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance: JACC CardioOncology State-of-the-Art Review JM Leerink, EC de Baat, EAM Feijen, L Bellersen, EC van Dalen, ... Cardio Oncology 2 (3), 363-378, 2020 | 83 | 2020 |
| Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects … MJ Ehrhardt, JM Leerink, RL Mulder, A Mavinkurve-Groothuis, W Kok, ... The Lancet Oncology 24 (3), e108-e120, 2023 | 50 | 2023 |
| Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review JM Leerink, SJ Verkleij, EAM Feijen, AMC Mavinkurve-Groothuis, ... Heart 105 (3), 210-216, 2019 | 42 | 2019 |
| Refining the 10-year prediction of left ventricular systolic dysfunction in long-term survivors of childhood cancer JM Leerink, HJH van der Pal, LCM Kremer, EAM Feijen, PG Meregalli, ... Cardio Oncology 3 (1), 62-72, 2021 | 33 | 2021 |
| Identification of patients at risk of sudden cardiac death in congenital heart disease: The PRospEctiVE study on implaNTable cardIOverter defibrillator therapy and suddeN … JT Vehmeijer, Z Koyak, JM Leerink, AH Zwinderman, L Harris, R Peinado, ... Heart Rhythm 18 (5), 785-792, 2021 | 32 | 2021 |
| Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of … EC de Baat, EC van Dalen, RL Mulder, MM Hudson, MJ Ehrhardt, ... The Lancet Child & Adolescent Health 6 (12), 885-894, 2022 | 29 | 2022 |
| Diagnostic tools for early detection of cardiac dysfunction in childhood cancer survivors: methodological aspects of the Dutch late effects after childhood cancer (LATER … JM Leerink, ELAM Feijen, HJH van der Pal, WEM Kok, ... American Heart Journal 219, 89-98, 2020 | 23 | 2020 |
| Asymptomatic systolic dysfunction on contemporary echocardiography in anthracycline-treated long-term childhood cancer survivors: a systematic review R Merkx, JM Leerink, EC de Baat, EAM Feijen, WEM Kok, ... Journal of Cancer Survivorship, 1-15, 2022 | 18 | 2022 |
| Echocardiography protocol for early detection of cardiac dysfunction in childhood cancer survivors in the multicenter DCCSS LATER 2 CARD study: design, feasibility, and … R Merkx, JM Leerink, ELAM Feijen, LCM Kremer, EC de Baat, L Bellersen, ... Echocardiography 38 (6), 951-963, 2021 | 17 | 2021 |
| Extensive cardiac function analyses using contemporary echocardiography in childhood cancer survivors: a DCCSS LATER study R Merkx, JM Leerink, ELAM Feijen, EC de Baat, L Bellersen, D Bresters, ... Cardio Oncology 5 (4), 472-485, 2023 | 11 | 2023 |
| Extracellular matrix remodeling in animal models of anthracycline-induced cardiomyopathy: a meta-analysis JM Leerink, M van de Ruit, EAM Feijen, LCM Kremer, ... Journal of Molecular Medicine 99 (9), 1195-1207, 2021 | 10 | 2021 |
| Cardiac function in childhood cancer survivors treated with vincristine: echocardiographic results from the DCCSS LATER 2 CARD study R Merkx, ELAM Feijen, JM Leerink, EC de Baat, L Bellersen, ... International journal of cardiology 369, 69-76, 2022 | 5 | 2022 |
| Candidate Plasma Biomarkers to Detect Anthracycline‐Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study JM Leerink, EAM Feijen, PD Moerland, EC De Baat, R Merkx, ... Journal of the American Heart Association 11 (14), e025935, 2022 | 3 | 2022 |
| A biomarker-based diagnostic model for cardiac dysfunction in childhood cancer survivors JM Leerink, EAM Feijen, EC de Baat, R Merkx, HJH van der Pal, ... Cardio Oncology 6 (2), 236-247, 2024 | 2 | 2024 |
| Risk prediction models for myocardial dysfunction and heart failure in patients with current or prior cancer EC van Dalen, JM Leerink, LCM Kremer, EAM Feijen Current oncology reports 25 (4), 353-367, 2023 | 2 | 2023 |
| Secondary prevention of anthracycline cardiotoxicity in childhood cancer survivors JM Leerink, EAM Feijen The Lancet Oncology 25 (2), 154-156, 2024 | 1 | 2024 |
| A call for harmonized surveillance recommendations in cardio-oncology JM Leerink, MJ Ehrhardt, EC van Dalen European Heart Journal 44 (31), 3017-3018, 2023 | 1 | 2023 |
| Towards evidence-based management of patients treated with cardiotoxic chemotherapy: A collaborative effort of cardiologists and oncologists JM Leerink, YM Pinto Netherlands Heart Journal 26, 519-520, 2018 | 1 | 2018 |
| Presence and utility of electrocardiographic abnormalities in long-term childhood cancer survivors EC de Baat, R Merkx, JM Leerink, C Boerhout, HJH van der Pal, ... Heart 110 (10), 726-734, 2024 | | 2024 |
| Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy: Novel Insights by Combining SNPs JM Leerink, EAM Feijen, LCM Kremer Cardio Oncology 5 (6), 819-820, 2023 | | 2023 |
Wouter KokMD PhD Cardiologist在 amc.uva.nl 的电子邮件经过验证
